Table 3.
Univariate and Multivariate Analysis of Factors Associated with PFS.
| Predictor | Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p Value | HR | 95% CI | p Value | |||
| NSAID use | 1.23 | 0.89 | 1.69 | 0.21 | 1.52 | 1.04 | 2.22 | 0.031 |
| Aspirin use | 1.18 | 0.86 | 1.61 | 0.30 | 1.39 | 0.95 | 2.04 | 0.087 |
| Male | 1.05 | 0.72 | 1.53 | 0.79 | — | |||
| Age at diagnosis | 1.00 | 0.99 | 1.01 | 0.91 | — | |||
| Age at treatment | 1.00 | 0.99 | 1.02 | 0.78 | 0.99 | 0.97 | 1.01 | 0.51 |
| Type of ICI | <0.001 | |||||||
| PD-1 inhibitors | Reference | Reference | ||||||
| PD-1 inhibitors/CTLA4 inhibitors | 0.94 | 0.63 | 1.39 | 0.74 | 1.26 | 0.66 | 2.42 | 0.48 |
| PD-1 inhibitors + TKI | 0.76 | 0.40 | 1.46 | 0.42 | 1.16 | 0.56 | 2.42 | 0.69 |
| PD-1 + interleukins under clinical trial | 0.38 | 0.23 | 0.61 | <0.001 | 0.43 | 0.22 | 0.85 | 0.016 |
| Histology subtype | 0.22 | |||||||
| Clear cell RCC | Reference | — | ||||||
| Non-clear cell RCC | 1.80 | 0.88 | 3.68 | 0.105 | — | |||
| IMDC risk | 0.02 | |||||||
| Favorable | Reference | Reference | ||||||
| Intermediate | 1.11 | 0.77 | 1.62 | 0.57 | 1.25 | 0.82 | 1.9 | 0.31 |
| Poor risk | 2.06 | 1.19 | 3.55 | 0.009 | 1.49 | 0.82 | 2.8 | 0.19 |
| Lines of prior therapies | 0.008 | |||||||
| 0 | Reference | Reference | ||||||
| 1 | 1.62 | 1.10 | 2.39 | 0.014 | 1.28 | 0.7 | 2.33 | 0.42 |
| 2 | 1.73 | 1.11 | 2.69 | 0.016 | 1.11 | 0.54 | 2.3 | 0.78 |
| 3 and more | 1.95 | 1.23 | 3.09 | 0.005 | 1.66 | 0.81 | 3.4 | 0.17 |
| High NLR | 1.18 | 1.11 | 1.25 | <0.001 | 1.15 | 1.08 | 1.23 | <0.001 |
Abbreviations: ICI, immune checkpoint inhibitor; IMDC, International Metastatic RCC Database Consortium Risk model; NLR, neutrophil-to-lymphocyte ratio; PD-1, programmed cell death protein 1; PFS, progression-free survival; RCC, renal cell carcinoma; TKI, tyrosine kinase inhibitor.